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Perspectives
Right to Try: Patient Advocacy for End of Life Drug Access
John Moon
Wh en it comes to cutting-edge therapies in medicine, we have heard the hope-inspiring story before; a 
terminally ill patient enrolls in a clinical trial and, against 
all odds, overcomes the disease. In 2011, Jenn McNary, 
mother of two young boys with Duchenne Muscular Dys­
trophy (DMD), embarked on such a story. Upon diagnosis 
of both her children with DMD, she was told that fatality 
was 100%. In 2011, she welcomed the hope that came 
with a clinical trial for a drug called Eteplirsen.' Only 
the younger child, however, qualified for the clinical trial.
As the clinical trial progressed, marked improvements in 
muscle development were apparent in her younger child 
Max. In sharp contrast, her older son Austin continued to 
deteriorate due to DMD; eventually he was unable to move 
his body. After three painful years of watching her older 
son slowly deteriorate, the Food and Drug Administration 
(FDA) finally permitted a clinical trial that Austin could 
join in 2014.^ Clinical trials offer a way for patients to ac­
cess investigational therapies. Many of the sickest, however, 
are often disqualified from participating. An estimated 97% 
of patients are unable to access or qualify for clinical trials.^ 
These patients have few options of resort.
The US is known to have one of the strictest drug 
approval and regulatory policies in the world. On average, 
it takes 12 years for an experimental drug to go from the 
laboratory bench to the pharmacy shelf'* The rigor and 
standard of the FDA comes with historical precedents that 
have revealed the widespread harm that can result from 
improper assessment and evaluation.** For the terminally 
ill, however, the potential benefit of a treatment outweighs 
the “risk” of inevitable death. The 12 years that it might take 
for a drug to possibly be approved by the FDA represents 
time precious to patients fighting for their lives.
In the area of improved drug access, patient ad­
vocacy has played an influential role. In response to the 
demands of AIDS patients for access to investigational 
drugs in the 1980s, the FDA initiated its Expanded Access 
Programs to allow limited access of investigational drugs 
outside the clinical-trial setting.® The number of approved 
Expanded Access Programs, however, has been minimal 
relative to patients' needs. For example, as of 2013 there 
were 60,000 ongoing clinical trials, but only 210 ongoing 
expanded access trials, less than 1 percent. And, in 2010, 
there were 1,014 patients approved for new investigational 
drug access across all diseases while there were 1,529,560 
new cases of cancer alone in the same year. As can be seen, 
there is a clear need for improvement in the area of drug 
access for terminally ill patients.
The FDA’s Expanded Access Program places a 
constraining conflict of interest against the needs of the 
patient. From the patient’s perspective, there is nothing 
to lose and everything to gain from a promising experi­
mental drug therapy. From the perspective of the FDA, it 
must protect the public from ineffective therapies. While 
hese two perspectives are not mutually exclusive, the FDA 
remains aware that it places its reputation and authority 
at risk with each newly approved therapy. As former FDA 
Commissioner Alexander Schmidt put it, “In all our FDA 
history, we are unable to find a single instance where a 
Congressional committee investigated the failure of the 
FDA to approve a new drug. But the times when hearings 
have been held to criticize our approval of a new drug 
have been so frequent that we have not been able to count 
them.”*' More testing over a longer time decreases the FDA’s 
risk for scrutiny.
While the FDA must protect the public from in­
effective therapies, its approach is flawed in the context of 
terminally ill patients. The FDA has noted that, “For a per­
son with a serious or life-threatening disease, who lacks a 
satisfactory therapy, a promising, but not yet fully evaluated 
product may represent the best available choice.”* Despite 
understanding a patient’s desperation for life, the FDA 
does not always support the decision of the individual and 
his/her doctor.’ In fact, the balance of power is completely 
sided with the FDA. The FDA is granted expansive veto 
power even in the face of support by both the will of the pa­
tient and the professional recommendation of a doctor. In 
simple terms, a patient’s chance of accessing life-supporting 
therapy -with the recommendation of medical counsel- can 
be denied by a bureaucratic veto from the FDA.
The sustainability of such an imbalance of power is 
untenable in light of patient advocacy for the terminally ill. 
“The Right to Try” legislation designed by the Goldwater 
Institute addresses many of the present concerns in order 
to rectify terminal patients’ rights. With The Right to Try 
legislation, patients are able to circumvent governmental 
regulation when the following conditions are met:
1. The patient has been diagnosed with a terminal 
disease.
2. The patient has considered all available treatment 
options.
3. The patient’s doctor has recommended that the in­
vestigational drug, device, or biological product represents 
the patient’s best chance at survival.
4. The patient or the patient’s guardian has provided 
informed consent.
5. The sponsoring company chooses to make the 
investigational drug available to patients outside the clinical 
trial.
The central tenets of The Right to Try are rooted 
in the concept of personal liberty. With full bipartisan 
support, the legislation has been passed in 30 states, most
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recently in West Virginia.'” This legislation acts to protect 
the interests of the patient and uphold the patient s con­
stitutional rights to medical autonomy. While the FDA’s 
drug approval and regulatory processes may hold a rational 
framework in the context of non-terminal patients, it di­
rectly opposes precedent Supreme Court cases that confirm 
an individual’s, “right to care for one’s health and person.”" 
The right to try, after all, should be in the hands of the dy­
ing individual, should it not?
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